Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $217.4 million.

  • Revolution Medicines' Cash & Equivalents rose 8.04% to $217.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.4 million, marking a year-over-year increase of 8.04%. This contributed to the annual value of $543.1 million for FY2024, which is 21.99% down from last year.
  • Latest data reveals that Revolution Medicines reported Cash & Equivalents of $217.4 million as of Q3 2025, which was down 45.97% from $402.4 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Cash & Equivalents registered a high of $696.1 million during Q4 2023, and its lowest value of $97.7 million during Q1 2022.
  • Over the past 3 years, Revolution Medicines' median Cash & Equivalents value was $358.4 million (recorded in 2023), while the average stood at $374.9 million.
  • As far as peak fluctuations go, Revolution Medicines' Cash & Equivalents surged by 715.82% in 2021, and later tumbled by 72.22% in 2022.
  • Over the past 5 years, Revolution Medicines' Cash & Equivalents (Quarterly) stood at $108.5 million in 2021, then soared by 48.77% to $161.4 million in 2022, then skyrocketed by 331.29% to $696.1 million in 2023, then decreased by 21.99% to $543.1 million in 2024, then increased by 8.04% to $217.4 million in 2025.
  • Its Cash & Equivalents stands at $217.4 million for Q3 2025, versus $402.4 million for Q2 2025 and $333.6 million for Q1 2025.